Key points are not available for this paper at this time.
Since the identification of SARS-CoV2 at the end of 2019, the COVID-19 pandemic has affected more than 410 million people worldwide and killed almost 6 million 1, 2. The predecessors of COVID-19 ( i.e. , SARS for severe acute respiratory syndrome and MERS for Middle-East respiratory syndrom) had been relatively self-limiting, preventing clinicians and researchers from establishing evidence-based specific therapeutic strategies 3. Conversely, COVID-19 rapidly proved to be extremely fast spreading, which led stakeholders to encourage, guide, build or fund multidirectional therapeutic research strategies based on both repurposing and development of new agents 4–8. The authors wish to thank Kristel Paque and Krizia Tuand, the biomedical reference librarians of the KU Leuven Libraries – 2Bergen – learning Centre Désiré Collen (Leuven, Belgium), for their help in conducting the systematic literature search.
Roche et al. (Thu,) studied this question.